 March 04, 2026

Its modular architecture supports cross-domain knowledge transfer, providing a universal intelligent foundation for upper-layer vertical industry engines. Downstream applications cover strategic sectors including new energy batteries, semiconductor materials, pesticide molecules, and high-temperature resistant alloys.

 January 21, 2026

Leveraging vast volumes of professional literature from both Chinese and international sources, physicians can utilize the DeepSearch feature not only to access the latest frontier guidelines across various specialty fields promptly but also to employ AI tools for literature review, significantly saving time and effort in information gathering and organization.

 February 24, 2026

Independently developed by Sciwind Biosciences as a new-generation cAMP-biased GLP-1 receptor agonist, Ecnoglutide injection has demonstrated robust efficacy and a favorable safety profile across multiple clinical studies, owing to its unique biased mechanism. In Chinese patients, it achieved a placebo-adjusted mean weight loss of 15.1%, with 92.8% of patients attaining clinically meaningful weight loss, and over 80% of patients achieving glycemic targets (HbA1c < 7.0%).

 March 03, 2026

Candid's operator, Ken Song, is a serial entrepreneur in the U.S. biopharmaceutical sector. His previous company, RayzeBio, took only three years from its founding to being acquired by BMS for $4.1 billion. The core capabilities of Ken Song's team were summarized by Wu Chenbing, CEO of partner EpimAb Biotherapeutics, into three points: strong scientific judgment, rapid team assembly, and high capital cohesion ability.